Taken together, the results of both gain-of-function and loss-of-function studies of mTORC1 activity, combined with an MLL-AF9 murine model, suggest that mTORC1 activity in osteoblasts contributes to AML progression. Here, KMT2A is linked to acute myeloid leukemia.